A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Treeline Biosciences, Inc.
Bayer
Shanghai Henlius Biotech
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hummingbird Bioscience
Boehringer Ingelheim
Novartis
Astellas Pharma Inc
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
AVEO Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Pfizer
Pfizer
Seagen Inc.
Fate Therapeutics
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
Revolution Medicines, Inc.
Pfizer
Erasca, Inc.
Erasca, Inc.
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
AstraZeneca
Allist Pharmaceuticals, Inc.
Incyte Corporation
Multitude Therapeutics Inc.
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Pfizer
D3 Bio (Wuxi) Co., Ltd
Quanta Therapeutics
R-Pharm
R-Pharm